08 Sep How are the genes in the TreatGxPlus pharmacogenetic test selected?
The TreatGxPlus pharmacogenetic test was developed using an evidence-based approach, following a rigorous review process of scientific studies and professional guidelines. This process allows us to select genetic variants with strong evidence for a significant clinical outcome indicating a change in dose of a medication, or a change of medication.
Review: Scientific studies and professional guidelines (PharmGKB, CPIC – Clinical Pharmacogenetics Implementation Consortium, DPWG – Dutch Pharmacogenetics Working Group) are reviewed to identify genetic variants with high level of evidence for clinical effect on medications.
Filter: The genetic variants that affect medication response and have clinical significance are filtered for usefulness in conditions most commonly managed in primary care.
Synthesis: The evidence behind each filtered genetic variant is investigated in more detail: clinical trials are evaluated, meta-analyses are performed, and forest plots are produced.
Presentation: The results from the evidence synthesis are presented to a team of expert geneticists, pharmacists, physicians, and epidemiologists to determine if the evidence behind the pre-selected genetic variants demonstrates a significant and useful clinical outcome.
Selection: Following the results from the evidence synthesis and recommendations from the team of experts, the genetic variants with strong evidence for changing or adjusting medication therapy are included in the TreatGxPlus gene panel.
In Canada, TreatGxPlus is brought to you in partnership with LifeLabs